Cancer Diagnostics Market Poised to Expand at a Robust Pace Over 2020

Cancer is a complex and potentially fatal disease that is primarily caused through environmental factors resulting in gene mutations affecting critical cell-regulatory proteins. These factors may act together or in a sequence to trigger tumor formation. Rising incidences of cancer and increasing healthcare expenditure are expected to aid the global cancer diagnostics market. The global market for cancer diagnostics is expected to grow at an exponential rate pertaining to advances in technology, favorable government initiatives and funding. Moreover, the development in companion diagnostics and advent of breakthrough detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the demand for cancer diagnostic devices. Cancer screening is critical in improving early detection and treatment of any cancer type. Awareness and screening for cancer have increased over the last couple of decades resulting in early diagnosis of cancer and subsequent reduction of mortality. However, the ultimate goal of reducing mortality in late-stage cancer has not been satisfactorily achieved

Obtain the PDF containing Upcoming Market Trends of Cancer Diagnostics at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3637

The global cancer diagnostics market was valued at USD 100,994.5 million in 2013, and is expected to grow at a CAGR of 7.6% to reach an estimated value of USD 168,649.3 million by 2020. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers.

The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020.

On the basis of geography, the global cancer diagnostics market is segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. In 2013, North America was the largest market for cancer diagnostics followed by Europe. North America is expected to register growth at a CAGR close to 7.0% during the forecast period 2014 to 2020 owing to the rising adoption rate of preventive diagnostic techniques and increasing government initiatives for creating cancer awareness. Moreover, high prevalence and incidence rate of cancer, particularly lung, breast, and prostate cancer, among the population is the driving the growth of the market. In the Asia-Pacific region, developed nations such as Japan and Australia, along with developing nations such as China, India, Singapore, Thailand, etc., are the potential markets that offer enormous opportunities for uptake of cancer diagnostics.

Read the Present Market Status of Cancer Diagnostics at: http://www.transparencymarketresearch.com/cancer-diagnostics-market.html

The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.